TORONTO, Jan. 8, 2021 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that
Alvaro Torres, Khiron CEO and
director, will participate live at the ATB 9th Annual Institutional
Investor Conference being held on January 12-14,
2021 .
Mr. Torres is scheduled to participate in a panel
on Thursday, January 14, 2021 at 3:40pm ET as
well as host one-on-one investor meetings throughout the day.
Date: Thursday, January 14,
2021
Time: International cannabis panel 3:40pm ET
To attend the event visit: https://bit.ly/2XmxMn2
Recent Khiron Highlights
- First company in Colombia to export THC products with
shipments to Peru
- Appoints former Colombia Minister of
Finance Juan Carlos Echeverry as an independent member of
its Board of Directors
- Opens new, small-format clinic in Medellin, Colombia's 2nd largest
city, extending Company's LatAm clinic network
- Declared a National Strategic Project by the Government
of Colombia, accelerating administration processes for the
Company's strategic initiatives
- Doctor ZereniaTM telehealth platform attracts
25% of patients from outside of Bogota, expanding national
reach
- Colombian government extends medical health insurance coverage
to THC and CBD medical cannabis products
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the
leading medical cannabis provider in Colombia and the first company licensed in
Colombia for the cultivation,
production, domestic distribution and sales, and international
export of both low and high THC medical cannabis products. The
Company has filled medical cannabis prescriptions in Colombia, Peru and the UK, and is positioned to commence
sales of medical cannabis in Germany and Brazil in early 2021.
Leveraging wholly-owned medical clinics and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty. Its Wellbeing unit launched the
first branded CBD skincare brand in Colombia, with KuidaTM now marketed
in multiple jurisdictions in Latin
America, the US and UK. The Company is led by Co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced and diverse executive
team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-ceo-to-participate-at-atb-9th-annual-institutional-investor-conference-301203246.html
SOURCE Khiron Life Sciences Corp.